Global Hemostats and Tissue Sealants Market Size By Type (Hemostats, Tissue Sealants), By Application (Clinical Medicine, Scientific Research), By Region, And Segment Forecasts, 2023 to 2032

The Global Hemostats and Tissue Sealants Market was valued at USD 7.3 billion in 2023 and is projected to reach USD 13.1 billion by 2031, growing at a CAGR of 7.6% during the forecast period from 2023 to 2031. The market is driven by increasing surgical procedures worldwide, the rising prevalence of chronic diseases, and the growing demand for minimally invasive surgeries. Hemostats and tissue sealants play a vital role in controlling bleeding and facilitating faster wound healing, thereby enhancing surgical outcomes and patient recovery.

Drivers:

Rising Surgical Volumes Globally

With the increasing aging population and a higher incidence of chronic conditions such as cardiovascular disorders, orthopedic issues, and cancers, the volume of surgeries is rising globally. This, in turn, drives demand for hemostats and tissue sealants for better intraoperative management.

Technological Advancements in Hemostatic Agents

Innovations in formulation, biodegradability, and biocompatibility are fueling market growth. New-generation sealants and adhesives that offer stronger adhesion and faster hemostasis are increasingly being adopted in complex surgical procedures.

Growing Preference for Minimally Invasive Procedures

Minimally invasive surgeries require precise control over bleeding and quicker wound closure solutions, increasing reliance on advanced hemostats and tissue sealants to enhance surgical efficacy and recovery.

Restraints:

High Cost of Advanced Products

Premium pricing of advanced tissue sealants and hemostatic agents can limit adoption, especially in cost-sensitive regions and among smaller healthcare facilities.

Regulatory Hurdles and Product Recalls

The market is heavily regulated due to the sensitive nature of the products. Delays in approvals and instances of product recalls can negatively impact market growth and company reputation.

Opportunity:

Untapped Potential in Emerging Markets

Countries in Asia-Pacific and Latin America present vast growth opportunities due to rising healthcare expenditure, improving surgical infrastructure, and increasing patient awareness.

Rise in Ambulatory Surgical Centers (ASCs)

The expansion of ASCs is expected to drive demand for efficient hemostatic and sealing products that support quick patient turnaround, minimally invasive interventions, and cost-effective care.

Market by System Type Insights:

By system type, Active Hemostats held the largest market share in 2023 due to their superior efficacy in managing moderate to severe bleeding. These include thrombin-based and fibrin sealant-based solutions that are particularly popular in cardiovascular and hepatic surgeries. Passive Hemostats, such as oxidized cellulose and gelatin-based products, are also widely used in low-bleeding scenarios and are expected to witness steady growth.

Market by End-use Insights:

In terms of end-use, Hospitals dominated the market in 2023, accounting for over 60% of total revenue, owing to the high volume of surgical procedures and availability of advanced medical equipment. The Ambulatory Surgical Centers (ASCs) segment is anticipated to witness the fastest growth rate during the forecast period due to increasing outpatient surgical procedures and the rising trend of same-day discharges.

Market by Regional Insights:

North America led the global hemostats and tissue sealants market in 2023 due to a well-established healthcare infrastructure, high surgical volumes, and robust product approvals. Asia-Pacific is projected to grow at the fastest pace through 2031, driven by a rising elderly population, increasing medical tourism, and rapid healthcare modernization in countries such as China and India.

Competitive Scenario:

Prominent players in the market include Johnson & Johnson (Ethicon), Baxter International Inc., B. Braun Melsungen AG, Medtronic plc, Pfizer Inc., BD (Becton, Dickinson and Company), CryoLife Inc., Integra LifeSciences Holdings Corporation, CSL Behring, and Takeda Pharmaceutical Company Limited. These companies are focusing on mergers, acquisitions, and new product launches to strengthen their market position.

Key Market Developments:

In 2024, Baxter launched a next-gen fibrin sealant with enhanced bioadhesive properties, expanding its surgical portfolio.

Johnson & Johnson introduced a minimally invasive compatible hemostatic patch in 2023 targeting orthopedic and trauma surgeries.

In 2022, BD acquired a startup specializing in synthetic tissue adhesives to diversify its surgical product range.

Scope of Work – Global Hemostats and Tissue Sealants Market

Report Metric Details

Market Size (2023) USD 7.3 billion

Projected Market Size (2031) USD 13.1 billion

CAGR (2023-2031) 7.6%

Key Segments by System Type Active Hemostats, Passive Hemostats, Adhesives and Sealants

Key Segments by End-Use Hospitals, Ambulatory Surgical Centers, Specialty Clinics

Leading Region North America

Key Players Johnson & Johnson, Baxter, Medtronic, B. Braun, BD, Integra LifeSciences

Growth Drivers Rise in surgical procedures, tech advancements, demand for MIS

Opportunities Emerging market expansion, ASC penetration

FAQs:

1) What is the current market size of the Hemostats and Tissue Sealants Market?

The market was valued at USD 7.3 billion in 2023.

2) What is the major growth driver of the Hemostats and Tissue Sealants Market?

Rising global surgical volumes and technological innovations in hemostatic agents are the major growth drivers.

3) Which is the largest region during the forecast period in the Hemostats and Tissue Sealants Market?

North America is the largest region due to high surgical demand and advanced healthcare systems.

4) Which segment accounted for the largest market share in Hemostats and Tissue Sealants Market?

The Hospitals segment accounted for the largest market share in 2023.

5) Who are the key market players in the Hemostats and Tissue Sealants Market?

Key players include Johnson & Johnson, Baxter, Medtronic, B. Braun, BD, CryoLife, and Integra LifeSciences.